Chylous Ascites as a Presentation of Lymphangioleiomyomatosis

Julian H. McLain, MD1, Kevork Khadarian, MD1, Layla Shojaie, MD1, Richard Lubman, MD1, Ching-Fei Chang, MD1, Brett Lindgren, DO1, and Ling Shao, MD, PhD1

1Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA

ABSTRACT
A 35-year-old woman presented to the hospital with a 4-week history of large-volume chylous ascites refractory to paracentesis and new-onset dyspnea. Thoracic computed tomography revealed diffuse pulmonary cystic lesions with pleural effusions, and abdominal computed tomography showed ascites with large bilateral retroperitoneal masses displaying positron emission tomography avidity. Biopsy of the masses demonstrated lymphatic invasion by a perivascular epithelioid cell neoplasm, a smooth muscle tumor. The patient was diagnosed as having the sporadic form of lymphangioleiomyomatosis and was treated with the mammalian target of rapamycin pathway inhibitor sirolimus with clinical improvement.

INTRODUCTION
Lymphangiomyomatosis (LAM) is a rare progressive multisystem disease that almost exclusively affects women of childbearing age as either a sporadic form (S-LAM) or as part of a syndrome linked to the autosomal dominant disorder tuberous sclerosis LAM.1,2 The incidence for S-LAM is 1–2.6 cases per 1,000,000 women.3 The disorder is characterized by a diffuse proliferation of abnormal smooth muscle cells characteristic of a group of proliferative tumors termed perivascular epithelioid cell tumors.4 Patients typically present with pulmonary symptoms such as progressive dyspnea, cough, pneumothorax, hemoptysis, and chylous pleural effusions.5–7 Clinical suspicion for this disorder can be triggered by extrapulmonary manifestations. Renal angiomyolipomas are a common extrapulmonary finding in S-LAM, but chylous ascites, lymphatic cystic lesions, and axial/retroperitoneal lymphadenopathy can also be seen.8,9 However, S-LAM presenting with extrapulmonary symptoms alone is uncommon. Here, we present the case of a 35-year-old woman with LAM who presented with progressive abdominal distention and recurrent chylous ascites.

CASE REPORT
A 35-year-old woman without a significant medical history presented with abdominal distention and associated discomfort for the past 4 weeks. Her symptoms did not progress until 2 weeks before admission, at which time she received a large-volume paracentesis and was instructed to follow-up with her primary care physician. While awaiting that appointment, her symptoms recurred, prompting her to return to the medical center where she was admitted to the hospital. The patient reported that the abdominal discomfort was positional, diffuse, and not associated with oral intake. Associated symptoms included an unintentional 40-pound weight loss over 2 months and dyspnea on exertion. She had no nausea, vomiting, diarrhea, urination changes, decreased appetite, or reduced nutritional intake. The patient denied taking supplements or medications other than aripiprazole for bipolar disorder and levothyroxine for hypothyroidism, without recent dose adjustments. The patient had no known history of cardiac, renal, or liver disease. Social history was notable for lack of alcohol consumption.

On initial presentation, the patient was afebrile, normotensive, had normal sinus rhythm, tachypneic to 26/min, and hypoxemic, with SaO2 86% on room air. Her body mass index was 49 kg/m². An abdominal examination revealed a distended abdomen that was
diffusely tender to palpation without rebound or guarding and positive for a fluid wave. The pulmonary examination revealed bilateral lower lobe crackles. Laboratory test results were notable for a normal complete blood count and basic metabolic profile, alkaline phosphatase (65 U/L), aspartate aminotransferase (9 U/L), total bilirubin (0.2 mg/dL), hypoalbuminemia (2.7 g/dL) without an elevated globulin gap, international normalized ratio (1.06), an elevated thyroid stimulating hormone (4.4 mIU/mL), and normal free T4 (1.22 ng/dL). Urinalysis was negative for proteinuria. Serum antinuclear and double-stranded DNA antibodies were negative.

Diagnostic paracentesis revealed a light pink milky ascitic fluid. Analysis of the fluid revealed a nucleated cell count of 399/cumm with 38% neutrophils and markedly elevated triglycerides (1,734 mg/dL). Further analysis of the ascitic fluid included negative body fluid cultures and a negative Gram stain, and acid-fast bacillus stain. Cytology did not demonstrate malignant cells. Serum triglycerides were noted to be within normal range (86 mg/dL), and serum QuantiFERON-TB Gold was negative. A positron emission tomography and computed tomography demonstrated bilateral hypermetabolic retroperitoneal lymph nodes measuring up to 9.3 cm and small to moderate bilateral pleural effusions, both measuring fat attenuation (Figure 1). Also present were diffuse pulmonary cystic lesions that were well-defined, round, thin-walled, and did not display lobar predominance (Figure 1). A biopsy of the retroperitoneal lymph node showed a smooth muscle tumor, histologically positive for HMB45, SMA, desmin, D2-40, and with a low Ki-67 score consistent with a perivascular epithelioid cell tumor (Figure 2). Based on these findings, a diagnosis of S-LAM was made.

Although the patient’s abdominal pain improved after paracentesis, her respiratory status continued to deteriorate. She became progressively more tachypneic (35/min) and had increasing oxygen requirements (SpO₂ 80% on BiPAP). Given worsening pleural effusions, the patient had a chest tube placed with the return of chylous fluid, and she was placed on a high

---

**Figure 1.** Thoracic and abdominal positron emission tomography and computed tomography—(A) A transverse section of the abdomen, showing enlarged retroperitoneal lymphadenopathy, measuring up to 9.3 cm on the right (*) and 8.0 cm on the left (×). (B) Approximately the same transverse section of the abdomen as seen in panel A, 60 minutes after the administration of 18F-fluorodeoxyglucose, demonstrating diffuse bilateral cystic changes of the (C) upper and (D) lower lobes of the lung (arrow), and pleural effusions measuring fat attenuation.
No mitoses or significant atypia are identified (hematoxylin and eosin stain, 40× magnification) and the diagnosis is a characteristic HRCT of the chest.13 However, symptoms and radiographic evidence of disease with a plan to develop the benign tumors characteristic of LAM. These benign tumors can invade into the lymphatic system resulting in obstruction of lymphatic flow, causing chyle to accumulate in the thoracic and abdominal cavity.12

LAM is categorized as a cystic lung disease, as reflected by the American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines. The only required criterion for diagnosis is a characteristic HRCT of the chest.13 However, presenting symptoms can be extrapulmonary, and the pulmonary radiologic manifestations of LAM can be subtle and overlooked on initial imaging.14 The onus for diagnosis of a case presenting with chylous ascites may therefore be the responsibility of the internist or consulting gastroenterologist and argues for greater awareness of this systemic disease.

Treatment options for LAM were advanced in 2011, with the MILES trial showing that therapy with the mTOR inhibitor Sirolimus effectively stabilizes pulmonary function and reduces symptoms.15 Although long-term outcomes with sirolimus have not been well studied, there is no known cure for LAM and many patients experience progressive respiratory failure requiring evaluation for a lung transplant.16

DISCUSSION

Although S-LAM is rare pulmonary disease, chylous ascites is a well-documented presentation of this disorder.3,10 S-LAM is caused by somatic mutations in the tuberous sclerosis complex-1 (TSC1) and tuberous sclerosis complex-2 (TSC2) genes, which indirectly inhibit activity of the mammalian target of rapamycin complex 1 (mTORC1).11 Overactivity of mTORC1 causes excess cellular growth and proliferation and primes patients to develop the benign tumors characteristic of LAM. These benign tumors can invade into the lymphatic system resulting in obstruction of lymphatic flow, causing chyle to accumulate in the thoracic and abdominal cavity.12

DISCLOSURES

Author contributions: All authors contributed equally to this manuscript. JH McLain is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received June 1, 2020; Accepted September 4, 2020

REFERENCES

1. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: Chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998; 62(4):810–5.
2. Borovansky JA, Labonte HR, Boroff ES, Ruddy BE, Mayer AP. Lymphangiomyomatosis: A case report. J Womens Heal. 2009;18(4):535–8.
3. Taveira-DaSilva AM, Steagall WK, Moss J. Lymphangiomyomatosis. Cancer Control. 2006;13(4):276–85.
4. Koenig AM, QuaaS A, Ries T, et al. Perivascular epithelioid cell tumour (PEComa) of the retroperitoneum — A rare tumor with uncertain malignant behaviour: A case report. J Med Case Rep. 2009;3:62.
5. Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangiomyomatosis. A study of 69 patients. Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM®O’P). Medicine (Baltimore). 1999;78(3):321–37.
6. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangiomyomatosis. Chest. 1999;115(4):1041–52.
7. Johnson SR, Tattersfield AE. Clinical experience of lymphangiomyomatosis in the UK. Thorax. 2000;55(12):1052–7.
8. De Paou RA, Boelaart JR, Haenelbalcke CW, Matthys EG, Schurgers MS, De Vriese AS. Renal angiomyolipoma in association with pulmonary lymphangiomyomatosis. Am J Kidney Dis. 2003;41(4):877–83.
9. L’Hostis H, Deminiere C, Ferriere JM, Coindre JM. Renal angiomyolipoma: A clinicopathologic, immunohistochemical, and follow-up study of 46 cases. Am J Surg Pathol. 1999;23(9):1011–20.
10. Kanou T, Nakagiri T, Minami M, Inoue M, Shintani Y, Okumura M. Peritoneovenous shunt for chylous ascites after lung transplantation for lymphangiomyomatosis. Transpl Proc. 2012;44(5):1390–3.
11. Dodd KM, Dunlop EA. Tubercous sclerosis-A model for tumour growth. Semin Cell Dev Biol. 2016;52:3–11.
12. Glasgow CG, El-Chemaly S, Moss J. Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis. *Eur Respir Rev*. 2012; 21(125): 196–206.

13. Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: High-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management an Official American Thoracic Society/Japanese Respiratory Society clinical practice guideline. *Am J Respir Crit Care Med*. 2017;196(10):1337–48.

14. Chen YS, Memon P. Lymphangioleiomyomatosis manifesting as refractory chylothorax and chyloperitoneum. *BMJ Case Rep*. 2019;12(7):e229958.

15. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *N Engl J Med*. 2011;364(17):1595–606.

16. Salman J, Ius F, Sommer W, et al. Long-term results of bilateral lung transplantation in patients with end-stage pulmonary lymphangioleiomyomatosis. *Prog Transpl*. 2019;29(2):115–21.

Copyright: © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.